Puberty and Growth in Cystic Fibrosis: A Review
Nellie Hani1, Marissa Kilberg2, Sara Bartz3
1Department of Pediatric Endocrinology, University of Michigan, Ann Arbor, Michigan.
Insights
Cystic fibrosis (CF) historically causes delayed puberty and growth. New modulator therapies may alter these outcomes, but their full impact on height is still being studied.
Area of Science:
- Pediatric Endocrinology
- Pulmonology
- Genetics
Background:
- Cystic fibrosis (CF) is a chronic disease historically linked to delayed puberty and impaired growth.
- Potential mechanisms include malnutrition, inflammation, growth hormone axis alterations, corticosteroid use, and gonadotropin signaling changes.
- Previous studies indicate delayed puberty, reduced peak height velocity, and lower final adult height in people with CF (pwCF).
Purpose of the Study:
- To review the impact of highly effective modulator therapies (HEMT) on growth and puberty trajectories in youth with CF.
- To understand the evolving understanding of growth and puberty in the context of modern CF treatment.
Main Methods:
- Literature review of studies examining growth and puberty in pwCF.
- Analysis of early data on the effects of HEMT on growth parameters.
Main Results:
- The full impact of HEMT on height outcomes in pwCF is not yet fully understood.
- Early research is investigating changes in growth and puberty following HEMT initiation.
Conclusions:
- The long-term effects of HEMT on growth and pubertal development in cystic fibrosis require further investigation.
- Understanding these changes is crucial for optimizing long-term health outcomes in pwCF.
Abstract:
Cystic fibrosis (CF) is a chronic disease process that has historically been associated with delayed puberty and growth. Mechanisms for delayed growth and puberty in chronic disease include malnutrition, inflammation, alterations of the growth hormone axis, chronic corticosteroid use, and changes to gonadotropin signaling or release. Early evidence suggested that people with CF have delayed puberty, decreased peak height velocity, and decreased final adult height compared to the general population. Management of delayed puberty in CF typically involves addressing the underlying cause of delay, and evidence for the utility of growth hormone to optimize growth in people with CF is inconsistent. In the era of highly effective modulator therapies for CF, early studies are examining changes in the growth and puberty trajectory in youth with CF. The full impact of highly effective modulator therapy on height outcomes remains unclear.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Signs of Puberty
Cystic Fibrosis: Management
Sinus disease and chronic...
Nature and Nurture
Changes in the Appendicular Skeleton with Age
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...


